Vaccine Therapy and Chemotherapy With or Without Tetanus Toxoid Compared With Chemotherapy Alone in Treating Patients With Metastatic Colorectal Cancer
This trial is active, not recruiting.
|Treatments||alvac-cea-b7.1 vaccine, tetanus toxoid, folfiri regimen, fluorouracil, irinotecan hydrochloride, leucovorin calcium|
|Sponsor||Herbert Irving Comprehensive Cancer Center|
|Collaborator||National Cancer Institute (NCI)|
|Start date||December 2001|
|Trial identifier||NCT00027833, APL-COL13, CDR0000069082, CPMC-14534, CPMC-BB-IND-9911, FCCC-01015, NCI-G01-2033|
RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Tetanus toxoid may make tumor cells more sensitive to chemotherapy and vaccine therapy.
PURPOSE: Randomized phase II trial to study the effectiveness of chemotherapy and vaccine therapy with or without tetanus toxoid compared with chemotherapy alone in treating patients who have metastatic colorectal cancer.
|United States||No locations recruiting|
|Other Countries||No locations recruiting|
|Birmingham, AL||University of Alabama at Birmingham Comprehensive Cancer Center||no longer recruiting|
|Los Angeles, CA||USC/Norris Comprehensive Cancer Center and Hospital||no longer recruiting|
|Washington, DC||Lombardi Cancer Center||no longer recruiting|
|Tampa, FL||H. Lee Moffitt Cancer Center and Research Institute||no longer recruiting|
|Chicago, IL||Robert H. Lurie Comprehensive Cancer Center, Northwestern University||no longer recruiting|
|Chicago, IL||University of Chicago Cancer Research Center||no longer recruiting|
|New York, NY||Herbert Irving Comprehensive Cancer Center||no longer recruiting|
|Portland, OR||Earle A. Chiles Research Institute at Providence Portland Medical Center||no longer recruiting|
|Philadelphia, PA||Fox Chase Cancer Center||no longer recruiting|
|Scranton, PA||Scranton Hematology-Oncology||no longer recruiting|
|Ottawa, Canada||Ottawa Regional Cancer Centre||no longer recruiting|
|Toronto, Canada||Princess Margaret Hospital||no longer recruiting|
|Montreal, Canada||McGill University||no longer recruiting|
Male or female participants at least 18 years old.
DISEASE CHARACTERISTICS: - Histologically confirmed metastatic colorectal adenocarcinoma - No clinically active CNS metastases PATIENT CHARACTERISTICS: Age: - 18 and over Performance status: - ECOG 0-1 Life expectancy: - More than 6 months Hematopoietic: - Lymphocyte count at least 1,000/mm^3 - Granulocyte count at least 1,500/mm^3 - Platelet count at least 100,000/mm^3 - Hemoglobin at least 10 g/dL Hepatic: - Bilirubin less than 1.5 times upper limit of normal (ULN) - AST/ALT less than 3 times ULN (5 times ULN if liver metastases present) - Alkaline phosphatase less than 3 times ULN (5 times ULN if liver metastases present) - No hepatocellular dysfunction - No cirrhosis Renal: - Creatinine less than 2.5 mg/dL Cardiovascular: - No uncontrolled coronary artery disease - No symptomatic congestive heart failure Pulmonary: - No uncontrolled chronic obstructive lung disease Gastrointestinal: - No unsolved bowel obstruction or subobstruction - No uncontrolled Crohn's disease - No ulcerative colitis - No concurrent chronic diarrhea Immunologic: - HIV negative - No immunocompromised patients - No diagnosis of altered immune function, including: - Lupus erythematosus - Sjogren's syndrome - Scleroderma - Myasthenia gravis - Goodpasture's disease - Addison's disease - Hashimoto's thyroiditis - Active Graves' disease - No known allergy to egg products or neomycin - No prior adverse reaction to tetanus toxoid-containing vaccines Other: - No significant comorbid medical function - No uncontrolled infection - No unstable diabetes mellitus - No uncontrolled thyroid function abnormalities - No other malignancy within the past 5 years except basal cell carcinoma or adequately treated carcinoma in situ of the cervix - No other medical illness or mental status that would preclude study participation - No prior severe toxicity to adjuvant chemotherapy - Not pregnant or nursing - Negative pregnancy test - Fertile patients must use effective contraception during and for at least 3 months after study participation PRIOR CONCURRENT THERAPY: Biologic therapy: - No prior CEA-directed immunotherapy - No other concurrent immunotherapy Chemotherapy: - At least 6 months since prior adjuvant chemotherapy - No prior chemotherapy for metastatic disease - No other concurrent chemotherapy Endocrine therapy: - No concurrent daily use of systemic steroids - No concurrent nonsubstitutional hormonal therapy Radiotherapy: - No prior radiotherapy to more than 50% of all nodal groups - No concurrent radiotherapy except for palliative purposes involving less than 20% of bone marrow reserve Surgery: - No prior major organ allograft - Recovered from prior surgery Other: - At least 28 days since prior investigational products - No other concurrent investigational products
|Official title||Pilot Phase II Study of Safety and Immunogenicity of an ALVAC-CEA/B7.1 Vaccine Administered With Chemotherapy, Alone or in Combination With Tetanus Toxoid, as Compared to Chemotherapy Alone, in Patients With Metastatic Colorectal Adenocarcinoma|
|Description||OBJECTIVES: - Determine the safety of ALVAC-CEA-B7.1 vaccine and chemotherapy, with or without tetanus toxoid, vs chemotherapy alone in patients with metastatic colorectal adenocarcinoma. - Determine whether tetanus toxoid enhances the immune response in patients treated with the vaccine and chemotherapy. OUTLINE: This is a randomized, open-label, multicenter study. Patients are randomized to 1 of 3 treatment arms. - Arm I: Patients receive a priming dose of tetanus toxoid. Beginning 2 weeks later, patients receive tetanus toxoid and ALVAC-CEA-B7.1 vaccine subcutaneously (SC) once weekly for 3 weeks. Two weeks after the third vaccine administration, patients receive tetanus toxoid and ALVAC-CEA-B7.1 vaccine SC on day 1 and irinotecan IV over 90 minutes, leucovorin calcium IV, and fluorouracil IV on days 1, 8, 15, and 22. Treatment repeats every 6 weeks for 4 courses in the absence of disease progression or unacceptable toxicity. - Arm II: Patients receive ALVAC-CEA-B7.1 vaccine and chemotherapy as in arm I. - Arm III: Patients receive chemotherapy as in arm I. After completion of chemotherapy, patients with partial or complete response may receive ALVAC-CEA-B7.1 vaccine SC once weekly on weeks 1-3 and 6. PROJECTED ACCRUAL: A total of 90 patients (30 per treatment arm) will be accrued for this study.|
Call for more information